Category: Unified Patent Court
-
Brazilian appeals court rejects Edwards Lifesciences’ trade dress claims against Meril’s heart valve, upholds first-instance ruling
A São Paulo appeals court has denied Edwards Lifesciences’ bid to stop Meril’s MyVal heart valve on trade dress grounds, upholding a trial court’s full rejection of the claims.
-
Disney switches off 4K UHD and HDR in Germany, possibly other markets due to InterDigital’s UPC injunction
Disney continues to degrade the quality of its streaming offerings in Germany just to comply with InterDigital’s video patent injunctions.
-
UPC Roundup (1 week): CoA clarifies conditional revocation appeals; Dusseldorf limits NDA-based FRAND defenses; Milan enters default judgment; and more
This is a summary of developments in and around the UPC in the calendar week of July 19, 2026.
-
Dusseldorf UPC follows Mannheim on NDA-related issue in InterDigital v. Disney
The Dusseldorf Local Division followed the Mannheim Local Division’s approach to confidentiality disputes in FRAND litigation, holding that Disney must bear the consequences of refusing to permit disclosure of licensing negotiations conducted under an NDA.Â
-
Meet the PMAC’s newly appointed FRAND Guidelines Working Group
Simon Dack, the newly appointed Chair of the PMAC’s FRAND Guidelines Working Group, as well as several of its members, shared with ip fray what this means for the SEP ecosystem.
-
BREAKING: UPC grants InterDigital second 11-country injunction against Disney
The UPC’s Dussledorf Local Division has today granted InterDigital the company’s second HEVC patent injunction against Disney, joining the several it has already secured in Germany and Brazil.
-
UPC Court of Appeal establishes framework for conditional revocation counterclaims
The UPC Court of Appeal established the first appellate framework for conditional revocation counterclaims, clarifying appeal rights, procedural requirements, and case management where infringement findings are challenged on appeal.
-
Awaiting potential $1.3B Moderna payout, Arbutus expands Covid-19 patent fight to Pfizer, BioNTech in Canada and UPC
Arbutus and Genevant have filed new lawsuits against Pfizer and BioNTech in Canada and the UPC over lipid nanoparticle patents, days after collecting $178 million from their Moderna settlement.
-
UPC Roundup (1 week): CoA clarifies appellate procedure; Dusseldorf revokes inspection order; FRAND counterclaims head to appeal; and more
This is a summary of developments in and around the UPC in the calendar week of July 12, 2026.
-
FRAND counterclaims against patent pools in UPC cases: Court of Appeal will have to decide after Hague LD denies preliminary objection
The UPC CoA will have to clarify whether FRAND counterclaims can be brought against pool administrators, which would have serious implications for the standards ecosystem.